

CITATION REPORT

List of articles citing

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

DOI: 10.1111/j.1742-1241.2009.02143.x

International Journal of Clinical Practice, 2009, 63, 1395-406.

Source: <https://exaly.com/paper-pdf/46359883/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
219	Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. 2009 , 76 Suppl 5, S28-38		48
218	Defining the importance of daily glyceimic control and implications for type 2 diabetes management. 2009 , 121, 82-93		11
217	DPP-4 inhibitors in clinical practice. 2009 , 121, 70-100		27
216	Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge. 2009 , 37, 7-21		2
215	The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. 2009 , 29, 55S-67S		15
214	Erratum. <i>International Journal of Clinical Practice</i> , 2009 , 64, 277-277	2.9	
213	Saxagliptin. 2009 , 69, 2103-14		53
212	Appraisal of Saxagliptin as Treatment of Type 2 Diabetes. 2010 , 5, 111-117		2
211	Saxagliptin (Onglyza) for Type 2 Diabetes. 2010 , 115, 1081-1083		
210	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. 2010 , 18, 213-7		10
209	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , 3, 31-41	3.4	31
208	Clinical overview of saxagliptin for Type 2 diabetes management. 2010 , 5, 809-823		6
207	Saxagliptin (Onglyza): new DPP-4 inhibitor for type 2 diabetes. 2010 , 21, 40-42		
206	Chapter 1: The Discovery of the Dipeptidyl Peptidase-4 (DPP4) Inhibitor Onglyza—From Concept to Market. 2010 , 1-24		
205	[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus]. 2010 , 105, 163-75		
204	The evolving place of incretin-based therapies in type 2 diabetes. 2010 , 25, 1207-17		25
203	Glycaemic control in type 2 diabetes: targets and new therapies. 2010 , 125, 328-61		130

202	[Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: DPP-4 inhibitors. Contributions with respect to other families of oral antidiabetic agents]. 2010 , 42 Suppl 1, 33-40			1
201	Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. 2010 , 26, 540-9			143
200	[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. 2010 , 39, 114-8			1
199	New therapies for type 2 diabetes have added little to improve glycaemic control compared to conventional therapies. 2010 , 27, 72-74			
198	Emerging treatment options for type 2 diabetes. 2010 , 70, 631-44			42
197	Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. 2010 , 2, 7-19			12
196	Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. 2010 , 6, 17-26			1
195	Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. 2010 , 6, 233-7			11
194	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , Volume 3, 31-41	3-4		14
193	Saxagliptin for type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , Volume 3, 325-335	3-4		3
192	Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. 2010 , 5, 23-37			19
191	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , Volume 3, 117-124	3-4		3
190	Review: Saxagliptin: a review. 2010 , 10, 14-20			2
189	A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. 2010 , 122, 16-27			179
188	Hypoglycaemia in patients with type 2 diabetes: minimising the risk. 2010 , 10, 35-41			3
187	Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. 2010 , 44, 1046-53			15
186	Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. 2010 , 122, 71-80			39
185	Saxagliptin: New Therapy for Type 2 Diabetes. 2010 , 26, 123-128			

184	Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. 2010 , 67, 1515-25		23
183	Saxagliptin for type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , 3, 325-35	3-4	3
182	Can therapies that target the incretin system improve our ability to treat type 2 diabetes?. 2010 , 102, 511-23		5
181	Overcoming challenges in Type 2 diabetes management to improve patient outcomes. 2010 , 5, 741-751		1
180	Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. 2010 , 26, 2355-63		25
179	Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. 2010 , 122, 144-52		12
178	Saxagliptina, un nuevo inhibidor de la DPP-4 en el tratamiento de la diabetes mellitus tipo 2: aspectos novedosos. 2010 , 26, 445-447		
177	The authors respond:. 2010 , 34, 180-181		
176	Incretin-based therapy in chronic kidney disease. 2010 , 17, 439-49		5
175	Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. 2010 , 49, 573-88		119
174	DPP-4 inhibitors: what may be the clinical differentiators?. 2010 , 90, 131-40		77
173	Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. 2010 , 8, 405-18		66
172	Incretin-based therapy and type 2 diabetes. 2010 , 84, 389-413		18
171	Saxagliptin: a guide to its use in type 2 diabetes mellitus. 2010 , 26, 5-8		
170	Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. 2011 , 34, 69-77		18
169	Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes. 2011 , 72, 287-295		5
168	Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. 2011 , 35, 518-27		3
167	Type 2 Diabetes in Adults. 2011 , 77-137		3

166	Incretin-based therapies and their future in Type 2 diabetes mellitus. 2011 , 8, 143-152		1
165	Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. 2011 , 50, 253-65		81
164	Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. 2011 , 71, 1441-67		166
163	Pharmacological management of type 2 diabetes mellitus: an update. 2011 , 7, 392-405		54
162	The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. 2011 , 162, 818-825.e6		92
161	Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. 2011 , 124, S3-18		220
160	Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. 2011 , 124, S19-34		54
159	Comment on Gerich--DPP-4 inhibitors: what may be the clinical differentiators?. 2011 , 93, e3-4		
158	Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus. 2011 ,		
157	Place in therapy for liraglutide and saxagliptin for type 2 diabetes. <i>Southern Medical Journal</i> , 2011 , 104, 426-39	0.6	1
156	Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. 2011 , 6, 304-9		24
155	Traitement du diab�e en dehors de l'insuline. 2011 , 8, 1-20		
154	Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. 2011 , 171, 1542-50		69
153	Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. 2011 , 13, 7-18		367
152	Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. 2011 , 13, 99-117		30
151	Dipeptidyl peptidase-4 inhibitors and HbA1c target of . 2011 , 13, 594-603		82
150	Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. 2011 , 13, 604-14		17
149	Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. 2011 , 13, 523-32		107

148	Effects of saxagliptin on β cell stimulation and insulin secretion in patients with type 2 diabetes. 2011 , 13, 850-8		38
147	Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. <i>International Journal of Clinical Practice</i> , 2011 , 65, 1230-9	2.9	111
146	Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. 2011 , 33, 528-76		39
145	Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. 2011 , 33, 1005-22		35
144	Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. 2011 , 27, 362-72		57
143	The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. 2011 , 123, 189-201		25
142	Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. 2011 , 123, 63-70		13
141	From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. 2011 , 2011, 898913		15
140	Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. 2011 , 2, 230-5		20
139	Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. 2011 , 4, 1-12		13
138	Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. 2011 , 24, 26-35		5
137	Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. 2011 , 8, 150-9		56
136	Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. 2011 , 27, 863-9		52
135	Management of patients with type 2 diabetes. 2011 , 27, 1931-47		9
134	Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. 2011 , 123, 53-65		14
133	Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence. 2012 , 30, 3-12		24
132	Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician. 2012 , 124, 95-108		6
131	Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. 2012 , 28, 1635-45		25

130	Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies. 2012 , 44, 157-69	2
129	The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation. 2012 , 6, 665-73	11
128	The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. 2012 , 14, 65-73	15
127	Recent advances in incretin-based therapies. 2012 , 77, 489-99	54
126	Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. 2012 , 46, 1453-69	76
125	Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes. 2012 , 36, 9-14	3
124	DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. 2012 , 38, 89-101	133
123	Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. 2012 , 23, 132-6	14
122	Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. 2012 , 72, 229-48	16
121	Pharmacokinetic study of saxagliptin in healthy Chinese subjects. 2012 , 32, 465-73	9
120	Newer Diabetes Medications. 2012 , 375-417	
119	Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. 2012 , 28, 513-23	147
118	Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. 2012 , 34, 1909-19.e15	44
117	Insulin, other hypoglycemic drugs, and glucagon. <i>Side Effects of Drugs Annual</i> , 2012 , 34, 685-702	0.2
116	Incretin therapies for type 2 diabetes: what nurses need to know. 2012 , 10, 345-352	
115	Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. 2012 , 11, 6	61
114	Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. 2012 , 21, 1202-15	20
113	Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. 2012 , 28, 268-75	62

112	Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. 2012 , 34, 1247-1258.e22	200
111	DPP-4 inhibitors in the treatment of type 2 diabetes. 2012 , 83, 823-32	66
110	Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. 2012 , 37, 510-24	35
109	Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. 2012 , 14, 481-92	18
108	The design of the liraglutide clinical trial programme. 2012 , 14 Suppl 2, 4-12	8
107	Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. 2012 , 4, 8	13
106	Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2013 ,	3.6 7
105	Dipeptidyl Peptidase-4 Inhibitors. 2013 , 33-45	
104	Complementing insulin therapy to achieve glycemic control. 2013 , 30, 557-76	28
103	Saxagliptin overview: special focus on safety and adverse effects. 2013 , 12, 103-9	27
102	The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. 2013 , 19, 1050-61	23
101	Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. 2013 , 29, 921-9	23
100	The cardiovascular safety of incretin-based therapies: a review of the evidence. 2013 , 12, 130	33
99	Incretin-based therapies: focus on effects beyond glycemic control alone. 2013 , 4, 221-38	12
98	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. 2013 , 5, 241-53	8
97	The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. 2013 , 13, 307-18	20
96	Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. 2013 , 12, 60	35
95	Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials. 2013 , 125, 145-54	8

94	Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. 2013 , 20, 638-53		8
93	Self-Monitoring of Blood Glucose in Glucagon-Like Peptide-1-Based Treatment Approaches. 2013 , 26, 107-111		1
92	Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. <i>International Journal of Clinical Practice</i> , 2013 , 67, 307-16	2.9	61
91	Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. <i>International Journal of Clinical Practice</i> , 2013 , 67, 759-67	2.9	13
90	Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. 2013 , 30, 1472-6		25
89	Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥5 years) with inadequately controlled type 2 diabetes mellitus. 2013 , 8, 419-30		32
88	Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. 2013 , 6, 877-95		43
87	Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. 2014 , 20, 120-9		8
86	Assessment of pancreatic βcell function: review of methods and clinical applications. 2014 , 10, 2-42		119
85	Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥5 years) with type 2 diabetes. 2014 , 9, 1479-87		15
84	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. 2014 , 05,		1
83	The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. 2014 , 10, 787-812		42
82	Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. 2014 , 70, 1277-89		5
81	New and Future Medications for the Treatment of Type 2 Diabetes Mellitus. 2014 , 8, 260-280		1
80	Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. 2014 , 20, 1187-97		50
79	Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. 2014 , 30, 556-69		44
78	Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. 2014 , 32, 170-7		5
77	Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy. 2014 , 21, 198-210		10

76	Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult Chinese subjects. 2014 , 34, 763-72	3
75	Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. 2014 , 126, 19-32	23
74	Evidence-based practice use of incretin-based therapy in the natural history of diabetes. 2014 , 126, 66-84	9
73	Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. 2015 , 11, 9-23	9
72	Saxagliptin: a guide to its use in type 2 diabetes mellitus. 2014 , 30, 92-99	
71	Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. 2014 , 31, 289-317	7
70	Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. 2014 , 13, 33	49
69	Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study. 2014 , 34, 201-209	8
68	Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. 2014 , 5, 1-41	90
67	The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. 2014 , 30, 11-22	76
66	Composite endpoints in trials of type-2 diabetes. 2014 , 16, 492-9	19
65	A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. 2014 , 16, 443-50	40
64	Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy. 2014 , 28, 887-93	2
63	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. 2014 , 37, 2647-59	48
62	Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. 2014 , 14, 165-76	5
61	Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. 2014 , 6, 69	23
60	A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. 2014 , 14, 17	17
59	Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. 2014 , 105, 185-91	14

58	Implications of incretin-based therapies on cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2015 , 69, 531-49	2.9	10
57	Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. 2015 , 17, 868-77		17
56	Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. 2015 , 7, 313-23		2
55	Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes. 2015 ,		1
54	New pharmacological approaches to diabetes management. 2015 , 26, 140-146		1
53	Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. 2015 , 16, 8		5
52	Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. 2015 , 32, 1065-84		7
51	Pharmacologic treatment of type 2 diabetes: oral medications. 2015 , 49, 540-56		54
50	Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. 2015 , 7, 347-59		32
49	Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. 2015 , 38, 376-83		202
48	Incretin-based therapies for obesity treatment. 2015 , 64, 967-81		21
47	Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. 2015 , 33, 581-97		30
46	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. 2015 , 127, 463-79		10
45	Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. 2015 , 41, 19S-31S		5
44	Saxagliptin: A Review in Type 2 Diabetes. 2015 , 75, 1783-96		15
43	Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. 2015 , 38, 2018-24		58
42	Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. 2015 , 38, 2009-17		92
41	DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis. 2016 , 116, 288-98		46

40	DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. 2016 , 32, 391-404	47
39	Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. 2016 , 7, 527-35	2
38	Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. <i>BMJ, The</i> , 2016 , 353, i2231	5.9 47
37	Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). 2016 , 32, 289-96	42
36	Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. 2016 , 8, 809-815	8
35	Saxagliptin for the treatment of diabetes - a focus on safety. 2016 , 15, 697-707	6
34	A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. 2016 , 26, 374-9	1
33	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. 2017 , 19, 25	1
32	Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. 2017 , 8, 587-599	9
31	COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β CELL FUNCTION. 2017 , 23, 258-265	16
30	Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. 2017 , 7, 44865	19
29	The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study. 2017 , 8, 1147-1162	2
28	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. 2017 , 39, 1780-1789.e33	21
27	Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions. 2017 , 37, 219-232	7
26	Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. 2017 , 9, 667-676	8
25	Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017 , 10, 317-332	3.4 7
24	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. 2018 , 93, 217-239	57
23	Pharmacotherapy of type 2 diabetes: An update. 2018 , 78, 13-42	103

22	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. 2018 , 9, CD011798		27
21	Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. 2018 , 13, e0202563		8
20	Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. 2018 , 13, e0197321		13
19	Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus. <i>Metabolic Syndrome and Related Disorders</i> , 2018 , 16, 336-341	2.6	7
18	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , 2019 , 10, 376	5.7	36
17	Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 2101-2114	4	1
16	Management and treatment of diabetes mellitus. <i>Advances in Experimental Medicine and Biology</i> , 2012 , 771, 356-80	3.6	16
15	Neue Arzneimittel 2009. 2010 , 47-126		2
14	GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2011 , 53-74	3.2	26
13	Recent diabetes issues affecting the primary care clinician. <i>Southern Medical Journal</i> , 2011 , 104, 456-61	0.6	2
12	The role of incretin therapy at different stages of diabetes. <i>Review of Diabetic Studies</i> , 2011 , 8, 323-38	3.6	20
11	The alpha-cell as target for type 2 diabetes therapy. <i>Review of Diabetic Studies</i> , 2011 , 8, 369-81	3.6	42
10	New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , 3, 117-24	3.4	5
9	Extension of the group of incretin-targeted preparations: Saxagliptin [a new dipeptidyl peptidase-4 inhibitor. <i>Problemy Endokrinologii</i> , 2010 , 56, 52-60	0	
8	Insulin, other hypoglycemic drugs, and glucagon. <i>Side Effects of Drugs Annual</i> , 2011 , 33, 889-908	0.2	
7	Glibenclamide - profile of efficacy and safety. <i>Diabetes Mellitus</i> , 2011 , 14, 85-90	1.6	
6	The Efficacy and Safety of Saxagliptin in Haemodialysis Patients. <i>Open Journal of Nephrology</i> , 2013 , 03, 83-88	0	
5	Pharmacogenetic Aspects of Type 2 Diabetes Treatment. <i>Acta Biomedica Scientifica</i> , 2020 , 5, 13-23	0.3	

4	A dipeptidyl peptidase-4 inhibitor for adults with type 2 diabetes. <i>P and T</i> , 2010 , 35, 2-4	1.4	
3	Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes. <i>P and T</i> , 2010 , 35, 509-13	1.4	32
2	Intermolecular Interactions of Saxagliptin and Vildagliptin with Human Serum Albumin. <i>Journal of Applied Spectroscopy</i> , 2022 , 88, 1266-1275	0.7	1
1	Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , e068882	5.9	0